- Home
- REFI vs PROC Comparison
REFI vs PROC Comparison
Compare REFI & PROC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFI
- PROC
- Stock Information
- Founded
- REFI 2021
- PROC 1976
- Country
- REFI United States
- PROC Luxembourg
- Employees
- REFI N/A
- PROC N/A
- Industry
- REFI Real Estate Investment Trusts
- PROC Biotechnology: Pharmaceutical Preparations
- Sector
- REFI Real Estate
- PROC Health Care
- Exchange
- REFI Nasdaq
- PROC Nasdaq
- Market Cap
- REFI 306.1M
- PROC 203.1M
- IPO Year
- REFI 2021
- PROC N/A
- Fundamental
- Price
- REFI $15.39
- PROC $1.90
- Analyst Decision
- REFI Buy
- PROC
- Analyst Count
- REFI 2
- PROC 0
- Target Price
- REFI $20.00
- PROC N/A
- AVG Volume (30 Days)
- REFI 73.0K
- PROC 9.8K
- Earning Date
- REFI 11-07-2024
- PROC 11-12-2024
- Dividend Yield
- REFI 12.22%
- PROC N/A
- EPS Growth
- REFI N/A
- PROC N/A
- EPS
- REFI 1.97
- PROC 0.52
- Revenue
- REFI $55,186,946.00
- PROC $414,096,000.00
- Revenue This Year
- REFI N/A
- PROC $5.54
- Revenue Next Year
- REFI $4.51
- PROC $8.54
- P/E Ratio
- REFI $7.81
- PROC $3.68
- Revenue Growth
- REFI 5.63
- PROC N/A
- 52 Week Low
- REFI $13.86
- PROC $1.68
- 52 Week High
- REFI $17.65
- PROC $4.95
- Technical
- Relative Strength Index (RSI)
- REFI 42.89
- PROC 43.98
- Support Level
- REFI $15.37
- PROC $1.77
- Resistance Level
- REFI $15.85
- PROC $2.06
- Average True Range (ATR)
- REFI 0.13
- PROC 0.11
- MACD
- REFI -0.00
- PROC -0.02
- Stochastic Oscillator
- REFI 22.22
- PROC 25.86
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About PROC Procaps Group S.A.
Procaps Group SA is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. It develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements, and high-potency clinical solutions. The company's segment includes NextGel; Procaps Colombia; CAN; CASAND and Diabetrics. It generates maximum revenue from the Procaps Colombia segment.